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The incorporation of concanamycin A, a potent inhibitor of vacuolar ATPases, into membranes of dimyristoyl phosphatidylcholine has
been studied by using EPR of spin-labelled lipid chains. At an inhibitor/lipid ratio of 1:1 mol/mol, concanamycin A broadens the chain-
melting transition of the phospholipid bilayer membrane, and effects the lipid chain motion in the fluid phase. The outer hyperfine splitting of
a spin label at the C-5 position and the line widths of a spin label at the C-14 position of the lipid chain are increased by concanamycin A.
Considerably larger membrane perturbations are caused by equimolar admixture of a designed synthetic 5-(5,6-dichloro-2-indolyl)-2,4-
pentadienoyl V-ATPase inhibitor. These results indicate that concanamycin A intercalates readily between the lipid chains in biological
membranes, with minimal perturbation of the bilayer structure. Essentially identical results are obtained with concanamycin A added to
preformed membranes as a concentrated solution in DMSO, or mixed with lipid in organic solvent prior to membrane formation. Therefore,
the common mode of addition in V-ATPase inhibition assays ensures incorporation of concanamycin into the lipid bilayer milieu, which
provides an efficient channel of access to the transmembrane domains of the V-ATPase.
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The plecomacrolides concanamycin A and bafilomycin [7,8]. Comparison is also made with a synthetic 5-(5,6-A1 are potent inhibitors of vacuolar ATPases (V-ATPases),
with effectivity in the low nanomolar range (see, e.g., Refs.
[1,2]). Blocking the extracellular acidification that is medi-
ated by osteoclast V-ATPases provides a direct means of
inhibiting bone resorption, the pathology of which is asso-
ciated with osteoporosis [3,4]. The mechanism of membrane
action of hydrophobic V-ATPase inhibitors, such as con-
canamycin, which are thought to interact with the trans-
membrane Vo-sector of the ATPase [5,6] is thus of
considerable pharmacological interest.
In the present work, we characterise the interaction of
concanamycin A (see Scheme 1) with lipid bilayer mem-
branes by using EPR of phospholipids spin-labelled in
their sn-2 chain. This method is well-suited to studying the
interaction of hydrophobic drugs with lipid membranes0005-2736/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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E-mail address: dmarsh@gwdg.de (D. Marsh).dichloro-2-indolyl)-2,4-pentadienoyl V-ATPase inhibitor
that was designed according to structure–function relation-
ships of concanamycin and bafilomycin derivatives [9].
Intercalation of concanamycin between the lipid chains is
demonstrated here by broadening of the chain-melting
transition of the lipid membrane and by limited increases
in spin-label spectral anisotropy and line widths in the
fluid phase. Most significantly, quantitatively similar spec-
tral perturbations are produced by concanamycin added
exogeneously (in dimethyl sulfoxide, DMSO), as by direct
mixing of concanamycin with lipid prior to membrane
formation.
Dimyristoyl phosphatidylcholine (DMPC) was from
Avanti Polar Lipids (Alabaster, AL) and concanamycin A
(z 90% pure) from Fluka (Buchs, Switzerland). Spin-la-
belled phosphatidylcholines (1-acyl-2-[n-(4,4-dimethyloxa-
zolidine-N-oxyl) stearoyl]-sn-glycero-3-phosphocholine, n-
PCSL) were synthesized according to Ref. [10]. The inhibitor
5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6-pentam-
Scheme 1. Chemical structures of concanamycin A and INDOL0.
Fig. 1. EPR spectra of 5-PCSL spin label in DMPC membranes with (solid
lines) and without (dashed lines) 1:1 mol/mol concanamycin A. Spectra
were recorded at the temperatures indicated in the gel (14 jC), transitional
(24 jC) and fluid (39 jC) phases. Total scan width = 100 gauss.
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Scheme 1) was synthesized according to Refs. [11,12].
DMPC (in CH2Cl2) and concanamycin A (in MeOH)
were mixed in equimolar ratio, together with 0.5 mol% n-
PCSL, and the solution then evaporated with dry nitrogen.
After keeping under vacuum overnight, the dry mixture was
hydrated in 50 Al of 10 mM Hepes, 10 mM NaCl, 10 mM
EDTA, pH 7.8 buffer, with vortex mixing at 37 jC. Samples
containing INDOL0 were prepared similarly. Alternatively,
concanamycin was added, as a concentrated solution in 15
Al of DMSO, to the spin-labelled lipid dispersion already
hydrated in 200 Al of buffer. The dispersion was incubated
above the lipid chain-melting temperature and excess
DMSO then removed by centrifugation and washing. Ad-
dition of an equal volume of DMSO alone was used for a
control lipid dispersion. The lipid dispersions were finally
transferred to 1-mm diameter glass capillaries and pelleted
in a benchtop centrifuge. Excess supernatant was removed
and the capillaries were flame-sealed. All sample handling
was performed in glass vessels.
Conventional in-phase EPR spectra were recorded either
on a Varian Century Line, or on a Bruker EMX, 9 GHz
spectrometer that was thermostatted by nitrogen gas-flow.
The sample capillary was accommodated in a standard
quartz EPR tube that contained light silicone oil for thermal
stability. Temperature was measured by a fine-wire thermo-
couple located in the silicone oil at the top of the microwave
cavity. The membrane sample was centred vertically in the
rectangular TE012 resonator.
Fig. 1 shows EPR spectra of the 5-PCSL phosphatidyl-
choline spin label in membranes of DMPC, with or without
concanamycin A included in the membrane preparation.
Incorporation of concanamycin A decreases the mobility
(i.e., increases the spectral anisotropy) of 5-PCSL in both gel
and fluid phases of DMPC. The largest spectral changes are
found in the region of the chain-melting transition at 24 jC.Fig. 2A shows the temperature dependence of the maxi-
mum outer hyperfine splitting, 2Amax, from the 5-PCSL spin
label in DMPC membranes, with or without 1:1 mol/mol
concanamycin A. The values of Amax reflect the amplitude
(and in the slow-motion regime, also the rate) of motion of the
lipid chain segment at the C-5 position [13]. Incorporation of
concanamycin A within the hydrophobic interior of the
membrane is indicated by the broadening of the lipid chain-
Fig. 2. Temperature dependence of the outer hyperfine splittings, 2Amax, in
the EPR spectra of n-PCSL spin labels in DMPC membranes that are
formed in the presence (solid symbols) and absence (open symbols) of
equimolar concanamycin A, or in the presence of equimolar INDOL0
(crosses). (A) 5-PCSL spin label; (B) 14-PCSL spin label. In the region of
the transition and the intermediate gel phase, two-component spectra are
observed for 14-PCSL.
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decrease in Amax at 23 jC, for DMPC membranes in the
absence of the macrolide inhibitor. The increase in transition
width corresponds to a reduction in cooperativity of the lipid
chain packing by incorporation of concanamycin. The mid-
point of the transition is not shifted appreciably, which
indicates that concanamycin has no great preference for
association with fluid, as opposed to gel, DMPC lipids.
In the fluid La phase, the outer hyperfine splitting is
greater in the presence of concanamycin than in its absence.
Calculation of effective order parameters and isotropic hy-
perfine splitting constants throughout the fluid phase [14]
indicates that this spectral change corresponds to a limited
decrease in angular amplitude of chain-segmental motion,
rather than to any significant increase in environmental
polarity, by concanamycin (see, e.g., Ref. [15]). Below the
chain-melting transition, the lipid chain mobility is signifi-
cantly decreased by concanamycin in the intermediate ripple
phase (PhV), possibly by suppressing the pretransition. No
significant difference in chain mobility is detected at V 10 jC
in the LhV gel phase, however.Fig. 2B shows the temperature dependence of the outer
hyperfine splitting from 14-PCSL for which the spin-label is
situated deeper in the membrane than 5-PCSL, close to the
terminal methyl groups of the chains. In this case, there is
little difference in the values of Amax, with and without
concanamycin, in the fluid phase. This is because the EPR
spectra are essentially isotropic, corresponding to large-
amplitude segmental angular fluctuations at this position
of chain labelling, and concanamycin does not restrict the
amplitude of motion sufficiently to produce a significant
increase in Amax. Effects on spectral line widths are seen,
however, as are reflected by very small differences in the
effective values of Amax in the fluid phase (Fig. 2B). These
differences are in the same sequence and direction as the
much larger true changes in Amax that are recorded for 5-
PCSL in Fig. 2A. The line broadening effects for 14-PCSL
will be reported further below, in connection with exoge-
neous addition of concanamycin. In the intermediate gel
phase and transition region, the spectra of 14-PCSL consist
of two partially resolved components that correspond to
lipid populations of differing mobility. This coexistence of
spectral components, with varying relative intensity, is
indicated by the doubling of the data points at each
temperature and complicates the interpretation of the effects
of inhibitors in this region. A limited decrease in mobility by
concanamycin is observed in the low-temperature LhV gel-
phase. Whether a significant shift in transition temperature
is observed is difficult to decide from the temperature
dependence of Amax, but see further below.
For comparison, similar experiments were conducted
with the synthetic 5-(5,6-dichloro-2-indolyl)-2,4-pentadie-
noyl V-ATPase inhibitor INDOL0. Fig. 2A shows the
temperature dependence of the outer hyperfine splitting,
2Amax, from 5-PCSL in DMPC membranes containing
equimolar INDOL0. The perturbations of lipid mobility by
INDOL0 are considerably larger than those by equimolar
concanamycin A, especially in the fluid phase. Fig. 2B
shows corresponding data obtained with 14-PCSL. Within
the limitations for 14-PCSL that were already stated, these
data mirror the effects of INDOL0 relative to concanamycin
that are recorded by 5-PCSL. Equimolar INDOL0 attenuates
the lipid chain-melting transition (Fig. 2A), rather as does
cholesterol (see, e.g., Ref. [16]). Most likely, INDOL0 is
anchored at the lipid polar–apolar interface by the dipolar
properties of the indole group, as found for other indole-
containing amphiphiles [17].
Fig. 3A compares the effects, on the 5-PCSL outer
hyperfine splitting, of concanamycin added exogeneously
to preformed DMPC membranes with those in which con-
canamycin is codissolved with DMPC in organic solvent
during membrane preparation (i.e., as in Fig. 2). For these
experiments, a much smaller amount of lipid (100 Ag) was
dispersed in a larger volume of buffer than is normal in a
spin-label EPR experiment. This was done in order to
emulate better the conditions under which inhibition experi-
ments are routinely conducted. The consequent reduction in
   
   
Fig. 3. Effect of concanamycin on the temperature dependence of the EPR
spectra from n-PCSL spin labels in DMPC membranes. Solid symbols are
samples containing concanamycin A at 1:1 mol/mol nominal inhibitor/lipid
ratio, and open symbols are control DMPC membranes. ( –.– )
concanamycin premixed with DMPC in organic solvent (prior to membrane
formation); ( –n– ) concanamycin in DMSO added to preformed DMPC
membranes. Control for the latter (. . .5. . .) has 15 Al of DMSO, without
concanamycin, added. (A) Outer hyperfine splitting, 2Amax, of the 5-PCSL
spin label; (B) ratio of maximum spectral amplitude to double-integrated
intensity of the (first-derivative) spectrum of the 14-PCSL spin label.
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experimental measurements, compared with those in Fig.
2. Exogeneously added concanamycin produces a broaden-
ing of the chain-melting transition and increase in 2Amax in
the fluid phase that is similar to that produced by concana-
mycin mixed with lipid prior to membrane formation. To
within the experimental scatter, the perturbations produced
in the fluid phase by the two methods of addition also agree
quantitatively. Addition of DMSO to control membranes
produces little significant perturbation throughout the tem-
perature range studied (note that membranes are washed
subsequent to exogeneous addition of concanamycin, in
order to remove excess DMSO).
Fig. 3B shows the effects of concanamycin on the EPR
spectra of the 14-PCSL spin label in DMPC membranes.
Again, the two methods of inhibitor addition (exogeneously
and prior to membrane formation) are compared, and the
amount of lipid used is also that in Fig. 3A. The temperature
dependence of the 14-PCSL spectra is characterised by the
maximum (central) line height, normalised to the doubleintegral of the first-derivative EPR spectrum. The latter
represents the total spin label intensity, which should remain
constant. Therefore, the normalised line height is a sensitive
measure of spectral line broadening that is inversely pro-
portional to the square of the line width. Both broadening of
the chain-melting transition, and an increase in spectral
broadening in the fluid phase, are evident in Fig. 3B. In
contrast to the outer hyperfine splitting shown in Fig. 2B,
perturbation by concanamycin of the lipid mobility at the
chain ends is reflected by the increased line widths of the
pseudoisotropic 14-PCSL spectra. As for 5-PCSL in Fig.
3A, the extent of perturbation of 14-PCSL by concanamycin
is similar for the two methods of addition of the macrolide
inhibitor. Taking into account both Figs. 2B and 3B, little
shift in the chain-melting transition is evident, in agreement
with the measurements using 5-PCSL.
Even when added exogeneously, concanamycin A incor-
porates readily into the hydrophobic interior of lipid mem-
branes, where it perturbs the acyl chain motion at both the
C-5 and C-14 positions. The extent of chain perturbation is
limited, suggesting that the macrolide inhibitor is compat-
ible with the lipid bilayer structure. This is supported by the
fact that both fluid and gel phases are perturbed by con-
canamycin, with little preference between the two. The
ability of both concanamycin and the indole pentadiene
inhibitor to associate avidly with the lipid bilayer compo-
nent of biological membranes will increase their potency by
providing a two-dimensional diffusion channel [18] to the
inhibitory site in the transmembrane Vo-sector of the vacu-
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